Most weight lost with GLP-1 obesity drugs came from fat, while relative muscle mass was largely preserved. GLP-1 obesity drugs can lead to substantial weight loss, but an important question is what the body is actually losing. New research presented at the European Congress on Obesity (ECO2026) suggests that 80-85% of weight lost during treatment [...]

Un'analisi condotta dal professor Mark Taylor su quasi quindicimila pazienti svedesi ha associato l'uso di semaglutide a una riduzione del 21% dei ricoveri psichiatrici nei casi di disturbo bipolare. L'effetto, non riscontrato con altri farmaci GLP-1 come liraglutide, sembra legato alla capacità della molecola di ridurre l'infiammazione e lo stress cellulare nel cervello.

Un'analisi condotta dalla University of Pennsylvania su 12.000 pazienti affetti da diabete di tipo 2 e pubblicata su The BMJ ha rilevato che i farmaci agonisti del GLP-1 (come semaglutide e tirzepatide) comportano un rischio leggermente maggiore di caduta dei capelli rispetto ad altri antidiabetici. I pazienti in terapia con GLP-1 mostrano un rischio superiore del 37% rispetto a chi assume inibitori SGLT-2 e del 68% rispetto a chi usa inibitori DPP-4. L'incidenza reale resta comunque ridotta (1,6% dei casi) e riguarda forme di alopecia non cicatriziale: il fenomeno è in gran parte reversibile ed è causato dallo stress metabolico del rapido dimagrimento e da potenziali carenze nutrizionali.

Semaglutide was linked to greater weight loss and a 15% lower fracture risk in people with type 2 diabetes, raising the possibility of an unexpected bone health benefit. People with type 2 diabetes who took semaglutide experienced greater weight loss and a lower risk of bone fractures than those using several other weight-loss medications, according [...]

Semaglutide delivered dramatic weight loss and health benefits in adults over 65, offering new hope for healthier aging. A new analysis of data from the STEP clinical trial program suggests that semaglutide remains both effective and generally safe for older adults living with obesity. The research, conducted by Prof. Luca Busetto of the University of [...]

Ozempic and similar weight-loss drugs were linked to a striking 30% reduction in breast cancer risk in a study of more than 110,000 women. Popular weight-loss and diabetes medications such as Ozempic, Wegovy, Mounjaro, and Zepbound may offer an unexpected benefit beyond helping people lose weight. A large new study found that women taking these [...]

Researchers identified a strong association between GLP-1 medications and reduced rates of multiple substance use disorders, raising new questions about how these drugs may affect the brain’s reward system. What if some of the world’s most popular weight loss drugs are affecting more than appetite? A new study suggests that GLP-1 medications, a class of [...]

The most

A widely prescribed class of weight-loss and diabetes medications may be doing more than improving metabolic health. Drugs such as Ozempic and Wegovy have transformed the treatment of obesity and type 2 diabetes, helping millions lose weight and improve metabolic health. But scientists are increasingly uncovering effects that extend far beyond the scale. Research has [...]

Scientists may have found the brain-cell switch that determines how long Ozempic’s weight-loss effects last. Researchers at the National Institutes of Health (NIH) have gained new insight into how GLP-1 receptor agonists such as semaglutide produce their weight-loss effects. While scientists have long known which areas of the brain are involved, much less has been [...]